- 新型コロナウイルス
- 新型肺炎
- 韓国
「ムガンリ」の写真・グラフィックス・映像
- 提供元
- 日付
- 種類
- 向き
- カテゴリ
- 色
- 同義語オン
- 提供元
- 日付
- 24時間以内 0
- 48時間以内 0
- 72時間以内 0
- 7日以内 0
- 30日以内 0
- 1年以内 0
- 期間を指定 9
- 日付指定なし 9
- 種類
- 写真 9
- グラフィックス 0
- 映像 0
- 向き
- 縦 4
- 横 5
- 正方形 0
- カテゴリ
- ニュース
- スポーツ
- エンターテインメント
- 教育向け
- カテゴリ指定なし
- 色
- カラー 9
- モノクロ 0
- 同義語辞書
- 古い順
- 1
- 古い順
2020年05月04日New coronavirus New coronavirusNew coronavirus Vice Health Minister Kim Ganglip speaks during a press conference at the government complex in Seoul on May 4, 2020, about the spread of the new coronavirus in the country. South Korea reported eight more cases of the virus the same day, all of which came from overseas, as the country is set to further relax its monthslong social distancing guidelines amid a marked slowdown in new infections. (Yonhap)/2020-05-04 11:08:42/ ＜ 1980-2020 YONHAPNEWS AGENCY. .＞ (Newscom TagID: yonphotos166973) [Photo via Newscom]、クレジット：Ｙｏｎｈａｐｎｅｗｓ／ニューズコム／共同通信イメージズ
商品コード: 2020050901728
2021年02月05日Final meeting on Celltrion‘s COVID-19 treatment Final meeting on Celltrion‘s COVID-19 treatmentFinal meeting on Celltrion‘s COVID-19 treatment Food and Drug Safety Minister Kim Gang-lip (R) speaks during a final meeting on the conditional approval of Celltrion Inc.‘s CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, at the ministry in Cheongju, North Chungcheong Province, on Feb. 5, 2021. (Yonhap)/2021-02-05 11:35:04/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021020801110
2021年02月05日S. Korea OKs Celltrion‘s COVID-19 treatment for conditional use S. Korea OKs Celltrion‘s COVID-19 treatment for conditional useS. Korea OKs Celltrion‘s COVID-19 treatment for conditional use Food and Drug Safety Minister Kim Gang-lip speaks during a press conference at the ministry in Cheongju, North Chungcheong Province, central South Korea, on Feb. 5, 2021, on the conditional approval of pharmaceutical giant Celltrion Inc.‘s CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. (Yonhap)/2021-02-05 14:48:46/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021020808141
2021年02月08日Celltrion‘s COVID-19 treatment Celltrion‘s COVID-19 treatmentCelltrion‘s COVID-19 treatment Food and Drug Safety Minister Kim Gang-lip (R) views a sample of pharmaceutical giant Celltrion Inc.‘s COVID-19 antibody treatment, CT-P59, accompanied by the company‘s chief Seo Jung-jin, during his visit to a plant of the South Korean company in Incheon, west of Seoul, on Feb. 8, 2021. Celltrion‘s CT-P59 has won government approval on condition that it submits the results from its third clinical trial. (Yonhap)/2021-02-08 16:14:59/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021021004223
2021年03月05日Pfizer vaccine‘s approval Pfizer vaccine‘s approvalPfizer vaccine‘s approval Food and Drug Safety Minister Kim Gang-lip announces the approval of the use of Pfizer‘s COVID-19 vaccine, which will be introduced under a contract between the government and the American pharmaceutical company starting at the end of the month, after a final review meeting at the ministry in Cheongju, North Chungcheong Province, on March 5, 2021. (Yonhap)/2021-03-05 15:16:21/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021030808501
2021年05月21日Moderna vaccine‘s approval Moderna vaccine‘s approvalModerna vaccine‘s approval Food and Drug Safety Minister Kim Gang-lip announces the approval of the use of Moderna‘s COVID-19 vaccine after a final review meeting at the ministry in Cheongju, North Chungcheong Province, on May 21, 2021. (Yonhap)/2021-05-21 14:15:00/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021052410705
2021年08月10日Phase-3 clinical trial of local COVID-19 vaccinePhase-3 clinical trial of local COVID-19 vaccine Food and Drug Safety Minister Kim Gang-lip announces the approval of the phase-three clinical trial of SK Bioscience Co.‘s COVID-19 vaccine, GBP510, at the ministry in Cheongju, around 140 kilometers south of Seoul, on Aug. 10, 2021. (Yonhap)/2021-08-10 11:02:06/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞＝クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021081105798
2021年09月13日Int‘l bio conference in SeoulInt‘l bio conference in SeoulFood and Drug Safety Minister Kim Gang-li delivers an opening address at the 2021 Global Bio Conference at a Seoul hotel on Sept. 13, 2021. (Yonhap)/2021-09-13 15:22:51/＜Copyright ⓒ 1980-2021 YONHAPNEWS AGENCY. All rights reserved.＞、クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2021091415144
2022年01月12日S. Korea approves Novavax COVID-19 vaccineS. Korea approves Novavax COVID-19 vaccine Food and Drug Safety Minister Kim Gang-lip announces the permit for the use of U.S.-based biotechnology company Novavax Inc.‘s COVID-19 vaccine during a briefing at the agency in Cheongju, around 140 kilometers south of Seoul, on Jan. 12, 2022. The protein-based vaccine, Nuvaxovid, marks the fifth COVID-19 vaccine to get approval for use in South Korea, following the ones by AstraZeneca, Pfizer Inc., Johnson ＆ Johnson and Moderna Inc. (Yonhap)/2022-01-12 14:45:05/＜Copyright ⓒ 1980-2022 YONHAPNEWS AGENCY. All rights reserved.＞、クレジット：Ｙｏｎｈａｐ Ｎｅｗｓ Ａｇｅｎｃｙ／共同通信イメージズ
商品コード: 2022011211002
- 1
